{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:35:54Z","timestamp":1790775354330,"version":"4.1.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"DOI":"10.3389\/fcell.2020.00775","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T05:36:45Z","timestamp":1597124205000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Angiogenesis Inhibition by a Short 13 Amino Acid Peptide Sequence of Tetrastatin, the \u03b14(IV) NC1 Domain of Collagen IV"],"prefix":"10.3389","volume":"8","author":[{"given":"Alexia","family":"Vautrin-Glabik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Devy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Bour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Baud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Choulier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Hoarau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Dupont-Deshorgue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christ\u00e8le","family":"Sellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Brassart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Oudart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Ramont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Claude","family":"Monboisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Brassart-Pasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070978","article-title":"Are integrins still practicable targets for anti-cancer therapy?","volume":"11","author":"Alday-Parejo","year":"2019","journal-title":"Cancers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1517\/14712598.2012.646985","article-title":"Volociximab in cancer.","volume":"12","author":"Almokadem","year":"2012","journal-title":"Expert. Opin. Biol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"10414","DOI":"10.1093\/nar\/gkt792","article-title":"Dissecting the oligonucleotide binding properties of a disordered chaperone protein using surface plasmon resonance.","volume":"41","author":"Baltzinger","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/annonc\/mds281","article-title":"Phase Ib safety and pharmacokinetic study of volociximab, an anti-\u03b15\u03b21 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer.","volume":"24","author":"Besse","year":"2013","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00279","article-title":"\u03b21 integrins as therapeutic targets to disrupt hallmarks of cancer.","volume":"6","author":"Blandin","year":"2015","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00397","article-title":"Tumor microenvironment: extracellular matrix alterations influence tumor progression.","volume":"10","author":"Brassart-Pasco","year":"2020","journal-title":"Front. Oncol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029587","article-title":"Tetrastatin, the NC1 domain of the \u03b14(IV) collagen chain: a novel potent anti-tumor matrikine.","volume":"7","author":"Brassart-Pasco","year":"2012","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1038\/sj.bjc.6603171","article-title":"Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours.","volume":"94","author":"Cianfrocca","year":"2006","journal-title":"Br. J. Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00221","article-title":"Resistance mechanisms to anti-angiogenic therapies in cancer.","volume":"10","author":"Haibe","year":"2020","journal-title":"Front. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/nrc1094","article-title":"Basement membranes: structure, assembly and role in tumour angiogenesis.","volume":"3","author":"Kalluri","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"13775","DOI":"10.1073\/pnas.0803241105","article-title":"A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells.","volume":"105","author":"Karagiannis","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1158\/1535-7163.mct-06-0100","article-title":"A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo.","volume":"5","author":"Khalili","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28003-x","article-title":"Conformation-dependent binding of a Tetrastatin peptide to \u03b1v\u03b23 integrin decreases melanoma progression through FAK\/PI3K\/Akt pathway inhibition.","volume":"8","author":"Lambert","year":"2018","journal-title":"Sci. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1016\/j.bbagen.2013.12.029","article-title":"Matrikines from basement membrane collagens: a new anti-cancer strategy.","volume":"1840","author":"Monboisse","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"B15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1346-8138.2011.01483.x","article-title":"Antimicrobial peptides in the pathogenesis of psoriasis.","volume":"39","author":"Morizane","year":"2012","journal-title":"J. Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and autodocktools4: automated docking with selective receptor flexibility.","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.mvr.2007.05.005","article-title":"Type IV collagen-derived angiogenesis inhibitors.","volume":"74","author":"Mundel","year":"2007","journal-title":"Microvasc. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1242\/jcs.00673","article-title":"Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta 1 integrin.","volume":"116","author":"Orecchia","year":"2003","journal-title":"J. Cell Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"32999","DOI":"10.1074\/jbc.m005235200","article-title":"The alpha 3(IV)185-206 peptide from noncollagenous domain 1 of type IV collagen interacts with a novel binding site on the beta 3 subunit of integrin alpha Vbeta 3 and stimulates focal adhesion kinase and phosphatidylinositol 3-kinase phosphorylation.","volume":"275","author":"Pasco","year":"2000","journal-title":"J. Biol. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"8051","DOI":"10.1074\/jbc.275.11.8051","article-title":"New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo.","volume":"275","author":"Petitclerc","year":"2000","journal-title":"J. Biol. Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.2174\/138920111796117300","article-title":"Anti-angiogenic peptides for cancer therapeutics.","volume":"12","author":"Rosca","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/cancers5010027","article-title":"Integrin \u03b15\u03b21, the fibronectin receptor, as a pertinent therapeutic target in solid tumors.","volume":"5","author":"Schaffner","year":"2013","journal-title":"Cancers"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1091\/mbc.9.8.1969","article-title":"Integrin-mediated signaling events in human endothelial cells.","volume":"9","author":"Short","year":"1998","journal-title":"Mol. Biol. Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"17839","DOI":"10.18632\/oncotarget.24894","article-title":"Structural characterization and in vivo pro-tumor properties of a highly conserved matrikine.","volume":"9","author":"Silva","year":"2018","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/ijc.10958","article-title":"Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice.","volume":"104","author":"Stoeltzing","year":"2003","journal-title":"Int. J. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.1073\/pnas.0730882100","article-title":"Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins.","volume":"100","author":"Sudhakar","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010084","article-title":"Tumor angiogenesis and anti-angiogenic strategies for cancer treatment.","volume":"9","author":"Teleanu","year":"2019","journal-title":"J. Clin. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/bf00666038","article-title":"Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors.","volume":"36","author":"Weidner","year":"1995","journal-title":"Breast Cancer Res. Treat."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/82_2012_287","article-title":"Mechanisms of vessel regression: toward an understanding of the resolution of angiogenesis.","volume":"367","author":"Wietecha","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1515\/hsz-2018-0317","article-title":"Complexity of type IV collagens: from network assembly to function.","volume":"400","author":"Wu","year":"2019","journal-title":"Biol. Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1593\/tlo.08187","article-title":"alpha(5)beta(1) integrin ligand PHSRN induces invasion and alpha(5) mRNA in endothelial cells to stimulate angiogenesis.","volume":"2","author":"Zeng","year":"2009","journal-title":"Transl. Oncol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.00775\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T05:36:49Z","timestamp":1597124209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.00775\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":31,"alternative-id":["10.3389\/fcell.2020.00775"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2020.00775","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,11]]},"article-number":"775"}}